4-氨基-2-苯基苯甲酰甲硫氨酸甲酯 | 180977-03-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 4-氨基-2-苯基苯甲酰甲硫氨酸甲酯
• 英文名称: 4-amino-2-phenylbenzoylmethionine methyl ester
• 英文别名: 4-amino-2-phenylbenzoyl-L-methionine methyl ester；N-(4-Amino-2-phenylbenzoyl)methionine methyl ester；methyl (2S)-2-[(4-amino-2-phenylbenzoyl)amino]-4-methylsulfanylbutanoate
• CAS: 180977-03-1
• 化学式: C₁₉H₂₂N₂O₃S
• 分子量: 358.461
• InChiKey: MCSVVHVRYQWPDV-KRWDZBQOSA-N

物化性质

• 沸点：
  594.8±50.0 °C(Predicted)
• 密度：
  1.204±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  25
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  107
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-氨基-2-苯基苯甲酰甲硫氨酸甲酯 在 四丁基氟化铵 、 sodium cyanoborohydride 、 溶剂黄146 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 12.25h， 生成 [4-((2S,4R)-N-Boc-4-hydroxypyrrolidin-2-ylmethyl)amino-2-phenylbenzoyl]methionine methyl ester
  参考文献：
  名称：

  顺/反-3-和-4-羟基-2-氨基甲基吡咯烷衍生物的光信反应

  摘要：

  DOI：

  10.1002/bkcs.10374
• 作为产物：
  描述：

  N-[4-nitro-2-phenylbenzoyl]-methionine methyl ester 在 碳酸氢钠 作用下， 以 乙酸乙酯 为溶剂， 以0.24 g (73.4%)的产率得到4-氨基-2-苯基苯甲酰甲硫氨酸甲酯
  参考文献：
  名称：

  Inhibitors of farnesyltransferase

  摘要：

  公式为C.beta.X的肽类模拟物，其中C代表半胱氨酸，X代表任何自然存在的氨基酸，.beta.代表疏水间隔物，尤其是2-苯基-4-氨基苯甲酸。这些化合物是p2lras法尼基转移酶的有效抑制剂，可以阻断Ras依赖的致癌信号传导，并在动物模型中有效抑制人类肿瘤生长。还披露了通过功能化肽和肽类模拟物的末端氨基和羧基团制备的前药。这些功能化衍生物表现出增加的细胞摄取。还披露了其他结构修饰。

  公开号：

  US05834434A1

文献信息

• Inhibitors of prenyl transferases
  申请人：Univeristy of Pittsburgh

  公开号：US05965539A1

  公开（公告）日：1999-10-12

  Compounds which inhibit prenyl transferases, particularly farnysyltransferase and geranylgeranyl transferase I, processes for preparing the compounds, pharmaceutical compositions containing the compounds, and methods of use.

  抑制戊二烯基转移酶，特别是戊二烯基转移酶和戊二烯基转移酶I的化合物，制备这些化合物的方法，含有这些化合物的药物组合物，以及使用方法。
• Inhibitors of protein isoprenyl transferases
  申请人：University of Pittsburgh

  公开号：US20020193596A1

  公开（公告）日：2002-12-19

  Compounds having the formula 1 or a pharmaceutically acceptable salt thereof wherein R 1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L 2 —, and (i) heterocyclic-L 2 —; R 2 is selected from (a) 2 (b) —C(O)NH—CH(R 14 )—C(O)OR 15 , (c) 3 (d) —C(O)NH—CH(R 14 )—C(O)NHSO 2 R 16 (e) —C(O)NH—CH(R 14 )-tetrazolyl, (f) —C(O)NH-heterocyclic, and (g) —C(O)NH—CH(R 14 )—C(O)NR 17 R 18 ; R 3 is heterocyclic, aryl, substituted or unsubstituted cycloalkyl; R 4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L 1 is absent or is selected from (a) —L 4 —N(R 5 )—L 5 —, (b) —L 4 —O—L 5 —, (c) —L 4 —S(O) n —L 5 — (d) —L 4 -L 6 —C(W)—N(R 5 )—L 5 —, (e) —L 4 -L 6 —S(O) m —N(R 5 )—L 5 —, (f) —L 4 —N(R 5 )—C(W)—L 7 -L 5 —, (g) —L 4 —N(R 5 )—S(O) p —L 7 —L 5 —, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, and (j) optionally substituted alkynylene are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.

  具有以下公式的化合物或其药学上可接受的盐，其中R1为(a)氢，(b)较低的烷基，(c)烯基，(d)烷氧基，(e)硫代烷氧基，(f)卤素，(g)卤代烷基，(h)芳基-L2—，以及(i)杂环-L2—；R2从(a)中选择，(b) -C(O)NH-CH(R14)-C(O)OR15，(c)中选择，(d) -C(O)NH-CH(R14)-C(O)NHSO2R16，(e) -C(O)NH-CH(R14)-四唑基，(f) -C(O)NH-杂环，以及(g) -C(O)NH-CH(R14)-C(O)NR17R18；R3为杂环，芳基，取代或未取代的环烷基；R4为氢，较低烷基，卤代烷基，卤素，芳基，芳基烷基，杂环基，或(杂环)烷基；L1为空缺或从(a) -L4-N(R5)-L5-，(b) -L4-O-L5-，(c) -L4-S(O)n-L5-，(d) -L4-L6-C(W)-N(R5)-L5-，(e) -L4-L6-S(O)m-N(R5)-L5-，(f) -L4-N(R5)-C(W)-L7-L5-，(g) -L4-N(R5)-S(O)p-L7-L5-，(h)可选择取代的烷基，(i)可选择取代的烯基，以及(j)可选择取代的炔基是蛋白异戊二烯转移酶的抑制剂。还公开了蛋白异戊二烯转移酶抑制组合物和抑制蛋白异戊二烯转移酶的方法。
• [EN] INHIBITORS OF PRENYL TRANSFERASES<br/>[FR] INHIBITEURS DES PRENYLE TRANSFERASES
  申请人：UNIVERSITY OF PITTSBURGH

  公开号：WO1996021456A1

  公开（公告）日：1996-07-18

  (EN) Compounds which inhibit prenyl transferases, particularly farnysyltransferase and geranylgeranyl transferase I, processes for preparing the compounds, pharmaceutical compositions containing the compounds, and methods of use.(FR) L'invention a pour objet des composés inhibiteurs des prényle transférases, particulièrement, des farnysyltransférases et des géranylgéranyle transférases I. L'invention traite également de procédés de préparations de ces composés, de compositions pharmaceutiques contenant ces composés et de leurs procédés d'utilisation.

  (EN) 抑制戊二烯转移酶，尤其是戊二烯基转移酶和戊二烯基转移酶I的化合物，制备这些化合物的方法，包含这些化合物的制药组合物以及使用方法。 (FR) 本发明涉及抑制戊二烯转移酶的化合物，尤其是戊二烯基转移酶和戊二烯基转移酶I的化合物，制备这些化合物的方法，包含这些化合物的制药组合物以及使用方法。
• Compounds and methods for the inhibition of compounds cruzi
  申请人：Hamilton D Andrew

  公开号：US20060167269A1

  公开（公告）日：2006-07-27

  The present invention relates to compounds according to the formula (I): Where R A is a C 1 -C 10 substituted or unsubstituted linear, branch-chained or cyclic alkyl or alkenyl group or a phenyl group according to the formula (II): R B is a C 1 -C 10 substituted or unsubstituted linear, branch-chained or cyclic alkyl or alkenyl group or a phenyl group of the formula (III): R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 are each independently selected from H, C 1 -C 10 (preferably a C 1 -C 4 ) alkyl or alkenyl group, CF 3 , F, Cl, Br, I, CN, NO 2 , NH 2 , NHR, NRR, COR (acyl group), OR (hydroxyl or ether group), CO 2 R (carboxylic acid or ester group), or COSR (thioester group) where R is H or a C 1 -C 10 (preferably a C 1 -C 4 ) alkyl or alkenyl group, an unsubstituted or substituted aryl (preferably, phenyl) or heterocycle group, or a (IV) group, where R 3 is H, a C 1 -C 10 (preferably a C 1 -C 4 ) alkyl, alkenyl, ether or a thioether group; and R 11 and R 12 are independently selected from H or a C 1 -C 3 alkyl or alkenyl group, or a pharmaceutically acceptable salt thereof and methods for treating infections caused by protozoal, fungal and/or bacterial agents such as Trypanosoma cruzi, Mycobacterium spp., Leishmania spp., Cryptococcus spp., Aspergillus spp., Histoplasma spp., Candida spp., especially Candida albicans, Pneumocystis carinii, Trichophyton spp., Microsporum spp., Malassezia spp., Rhizopus spp., Pseudallescheria spp., Blastomyces dermatitidis and Coccidiodes spp., among others.

  本发明涉及式(I)的化合物：其中RA是C1-C10取代或未取代的线性、支链或环烷基或烯基或式(II)的苯基：RB是C1-C10取代或未取代的线性、支链或环烷基或烯基或式(III)的苯基：R1、R2、R3、R4、R5、R6、R7、R8、R9和R10各自独立地选自H、C1-C10(优选为C1-C4)烷基或烯基、CF3、F、Cl、Br、I、CN、NO2、NH2、NHR、NRR、COR（酰基）、OR（羟基或醚基）、CO2R（羧酸或酯基）或COSR（硫酯基），其中R是H或C1-C10(优选为C1-C4)烷基或烯基、未取代或取代的芳基（优选为苯基）或杂环基，或式(IV)的基团，其中R3是H、C1-C10(优选为C1-C4)烷基、烯基、醚或硫醚基；R11和R12各自独立地选自H或C1-C3烷基或烯基，或其药学上可接受的盐，以及用于治疗由原虫、真菌和/或细菌引起的感染的方法，例如Trypanosoma cruzi，Mycobacterium spp.，Leishmania spp.，Cryptococcus spp.，Aspergillus spp.，Histoplasma spp.，Candida spp.，特别是Candida albicans，Pneumocystis carinii，Trichophyton spp.，Microsporum spp.，Malassezia spp.，Rhizopus spp.，Pseudallescheria spp.，Blastomyces dermatitidis和Coccidioides spp.等。
• Probing the hydrophobic pocket of farnesyltransferase: aromatic substitution of CAAX peptidomimetics leads to highly potent inhibitors
  作者：Yimin Qian、Juan Jose Marugan、Renae D. Fossum、Andreas Vogt、Said M. Sebti、Andrew D. Hamilton

  DOI：10.1016/s0968-0896(99)00252-7

  日期：1999.12

  Cysteine farnesylation at the carboxylate terminal tetrapeptide CAAX of Ras protein is catalyzed by farnesyltransferase. This lipid modification is necessary for regulatory function of both normal and oncogenic Ras. The high frequency of Ras mutation in human cancers has prompted an intensive study on finding ways of controlling oncogenic Ras function. Inhibition of farnesyltransferase is among the most sought after targets for cancer chemotherapy. We report here the design, synthesis and biological characterization of a series of peptidomimetics as farnesyltransferase inhibitors. These compounds are extremely potent towards farnesyltransferase with IC50 values ranging from subnanomolar to low nanomolar concentrations. They have a high selectivity for farnesyltransferase over the closely related geranylgeranyltransferase-I. Structure-activity relationship studies demonstrated that a properly positioned hydrophobic group significantly enhanced inhibition potency, reflecting an improved complementarity to the large hydrophobic pocket in the CAAX binding site. (C) 1999 Elsevier Science Ltd. All rights reserved.